Aurobindo Pharma's subsidiary, CuraTeQ Biologics, has received a Notice of Compliance from Health Canada for its biosimilar Dyrupeg. The regulatory nod confirms the drug meets safety and quality ...

Aurobindo Pharma’s wholly owned subsidiary Auro Pharma acquires Khandelwal Laboratories’ non-oncology prescription ...

Aurobindo Pharma said its subsidiary CuraTeQ Biologics has received Health Canada’s compliance notice for its biosimilar ...

Aurobindo Pharma's CuraTeQ Biologics receives Health Canada approval for Dyrupeg, marking a major regulatory milestone for ...

Aurobindo Pharma said its subsidiary CuraTeQ Biologics has received a Notice of Compliance from Health Canada for its ...

Aurobindo Pharma's subsidiary receives Health Canada NOC for Dyrupeg, confirming its pegylated filgrastim biosimilar's safety ...

Aurobindo Pharma said the decision is aligned with CuraTeQ's strategic portfolio prioritisation. As per the arrangement, BioFactura would receive a licence fee and milestone payments.

Aurobindo Pharma Limited has revised timeline for completing its proposed captive solar power arrangement and equity ...

Aurobindo Pharma has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Clopidogrel Tablets USP 75mg, which is being launched. Clopidogrel Tablets USP ...

Aurobindo's wholly owned subsidiary, Aurobindo Pharma USA, has entered into a collaboration and license agreement with an unnamed global pharma company for the development and commercialization of ...

Hyderabad, India. (6th September, 2010) - Aurobindo Pharma is pleased to announce that it has entered into licensing and supply agreements with AstraZeneca, one of the world's leading ...

After a rough regulatory start to the year, India’s Aurobindo Pharma is charting plans for growth. The Hyderabad-based generics juggernaut will plow 3 billion Indian rupees (about $37.7 million) into ...